Ezetimibe Tablets

Project Image

Therapeutic Indication

Primary hypercholesterolemia
Mixed dyslipidemia
Reduction of LDL cholesterol
Adjunct to statin therapy
Prevention of cardiovascular risk
+91 85919 78885

Ezetimibe

Tablet

Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. Ezetimibe is used as an adjunctive therapy to a healthy diet to lower cholesterol levels in primary hyperlipidemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia (HoFH), and homozygous sitosterolemia (phytosterolemia).

Speciality Cholesterol Absorption Inhibitor
Tags Cardiac Care | Lipid Control
Strength
  • 10 mg
Packing Size
  • 10 Tablets

Check all Tablets Range

Click to know More

Mechanism

Ezetimibe mediates its blood cholesterol-lowering effect via selectively inhibiting the absorption of cholesterol and phytosterol by the small intestine without altering the absorption of fat-soluble vitamins and nutrients. The primary target of ezetimibe is the cholesterol transport protein Niemann-Pick C1-Like 1 (NPC1L1) protein. NPC1L1 is expressed on enterocytes/gut lumen (apical) as well as the hepatobiliary (canalicular) interface and plays a role in facilitating internalization of free cholesterol into the enterocyte in conjunction with the adaptor protein 2 (AP2) complex and clathrin. Once cholesterol in the gut lumen or bile is incorporated into the cell membrane of enterocytes, it binds to the sterol-sensing domain of NPC1L1 and forms a NPC1L1/cholesterol complex. The complex is then internalized or endocytosed by joining to AP2 clathrin, forming a vesicle complex that is translocated for storage in the endocytic recycling compartment.

Pharmacodynamics

It reduces total cholesterol and LDL cholesterol levels without significantly affecting triglycerides, leading to improved lipid profile and cardiovascular protection.

Pharamcokinetics

  • Absorption: Rapidly absorbed and converted to active glucuronide
  • Bioavailability: Moderate (variable)
  • Peak Plasma Time: 1–2 hours (parent drug), 4–12 hours (active metabolite)
  • Protein Binding: >90%
  • Metabolism: Hepatic and intestinal glucuronidation
  • Half-life: ~22 hours
  • Excretion: Feces (~78%), urine (~11%)

Side Effects

  • Headache
  • Abdominal pain
  • Diarrhea
  • Fatigue
  • Elevated liver enzymes (with statins)

Contraindication

  • Active liver disease (with statins)
  • Hypersensitivity to ezetimibe

Interaction

  • Cyclosporine
  • Bile acid sequestrants (reduced absorption)
  • Anticoagulants
  • Statins (monitor liver enzymes)

Warning and Precautions

  • Monitor liver function when used with statins
  • Use cautiously in hepatic impairment
  • Regular lipid monitoring required
  • Not recommended in moderate to severe liver disease
  • Not recommended during pregnancy or breastfeeding; use only if benefit outweighs risk under medical supervision.

Dosage

As directed by the Physician.

Disclaimer

All product details on this website are for reference and informational purposes only and are not directed at patients or consumers.
As a contract manufacturer, DM Pharma Pvt Ltd is not responsible for the marketing or end use of these products and disclaims all liability arising from reliance on this information.
Please consult a healthcare professional before using any medicinal product.